Ferric carboxymaltose for anemia in Crohn's disease patients at a tertiary center: A retrospective observational cohort study

Autor(es)

Nunes Siqueira, Natalia Souza ; Pascoal, Livia Bitencourt ; Rodrigues, Bruno Lima ; de Castro, Marina Moreira ; Correa Martins, Alan Sidnei ; Silva Araujo, Dante Orsetti ; Miani Gomes, Luis Eduardo ; Camargo, Michel Gardere ; Setsuko Ayrizono, Maria de Lourdes ; Leal, Raquel Franco

• Tipo de documento: Artigo Científico
• Fonte: WORLD JOURNAL OF CLINICAL CASES; v. 11, n. 12, p. 14-pg., 2023-04-26.

Resumo

BACKGROUNDAlthough the gastrointestinal tract is the most affected by Crohn's disease (CD), the condition triggers other consequent manifestations, and iron deficiency anemia (IDA) is one of the most common. Intravenous (IV) iron replacement is currently available through several drugs, such as ferric hydroxide sucrose and ferric carboxymaltose (FCM). However, the clinical management of these conditions can be challenging.AIMTo elucidate the drug's effectiveness, the present study analyzed, through medical records, the clinical and epidemiological data of a cohort of patients with active CD who received IV FCM for the IDA treatment.METHODSThis retrospective observational study included 25 patients with active CD, severe anemia, and refractory to previous conventional treatments. Patients were evaluated two times: During the last treatment with ferric hydroxide sucrose and treatment with FCM.RESULTSAfter treatment with FCM, parameters of IDA assessment significantly improved, serum hemoglobin (Hb) levels increased in 93% of patients (P < 0.0001), and in 44%, there was an increase of = 2 g/dL in a single application. In addition, 86% of the patients showed an increase in serum iron (P < 0.0001) and ferritin (P = 0.0008) and 50% in transferrin saturation (P = 0.01). The serum iron levels at baseline showed a negative association with the ileal and colonic CD and use of biologics and a positive association with patients who developed CD later in life after the age of 40 (A3) and with a stenosing (B2) and fistulizing (B3) phenotype. The values of Hb and hematocrit after ferric hydroxide sucrose treatment remained similar to those found before treatment. CONCLUSIONThis study demonstrated that FCM is an important therapeutic strategy for treating IDA in CD patients, achieving satisfactory results in refractory cases. (AU)

• Processo FAPESP: 21/02997-9 - Efeitos da Carboximaltose Férrica para Tratamento da Anemia Ferropriva em pacientes com doença de crohn
• Beneficiário: Dante Orsetti Silva Araujo
• Modalidade de apoio: Bolsas no Brasil - Iniciação Científica